Comprehensive review covers the cardiovascular, kidney, and weight loss effects of GLP-1 and related therapies for type 2 diabetes, synthesizing evidence across all three major outcome domains.
Heart + kidney + weightGLP-1 drugs now have proven benefits across all three major metabolic outcome domains from landmark clinical trials
What the researchers found
GLP-1 drugs provide proven benefits across cardiovascular, kidney, and weight domains, with newer dual and triple agonists potentially expanding these multi-organ effects.
Why it matters
Understanding the complete multi-organ benefit profile helps clinicians prescribe GLP-1 drugs not just for blood sugar but for comprehensive cardiometabolic protection.
The numbers in context
Multiple medication alternatives covered. Guidelines address patients at varied risk levels for cardiovascular and kidney complications.
How the study worked
Comprehensive review synthesizing cardiovascular outcome trials, kidney outcome trials, and weight management trials for GLP-1 and related therapies.
Who was studied
Adults with type 2 diabetes at varying cardiovascular and kidney risk levels
What this study cannot tell us
Comprehensive review scope means less depth on individual topics. Not all benefits are proven for all GLP-1 drugs. Newer agents have less long-term data.
How to read the evidence
Strong evidence: comprehensive review of major randomized outcome trials across three organ system domains.
When this study was published
Published in 2025. Incorporates the latest trial evidence including SELECT and FLOW results.
The bigger picture
GLP-1 drugs have evolved from glucose-lowering agents to comprehensive cardiometabolic protectors. This review captures the paradigm shift — these peptide drugs now prevent heart attacks, protect kidneys, and produce surgical-level weight loss.
Questions still open
- Do all GLP-1 drugs provide equal cardiovascular, kidney, and weight benefits?
- Should GLP-1 drugs be standard first-line therapy for all T2D patients?
- How do dual/triple agonists compare to monotherapy across all three outcome domains?
Common questions
Do GLP-1 drugs protect the heart AND kidneys?
Which GLP-1 drug has the best overall benefits?
Read the original research
Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.
BMJ (Clinical research ed.), 390, e082071
Citation
Agarwal, Arnav; Mustafa, Reem; Manja, Veena; Agoritsas, Thomas; Macdonald, Helen; Li, Sheyu; Foroutan, Farid; Rayner, Daniel; Rodriguez-Gutierrez, René; Åsvold, Bjørn Olav; Heen, Anja Fog; Gabi, Jenan; Guo, Lixin; Hao, Qiukui; Jeppesen, Britta Tendel; Jha, Vivekanand; Nagler, Evi; Odom, Adrienne; Rodondi, Nicolas; Shetty, Sahana; Vermandere, Mieke; Wright, Robin; Guyatt, Gordon; Vandvik, Per Olav. (2025). Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.. BMJ (Clinical research ed.), 390, e082071. https://doi.org/10.1136/bmj-2024-082071